Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CLSevere and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.Cancer Chemother Pharmacol 71(5) 1183-90 5/1/2013
Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161(3) 156-64 3/1/2013
Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder SHedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.Cancer Res 72(19) 5048-59 10/1/2012
Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CLPhase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.Cancer Chemother Pharmacol 70(1) 49-56 7/1/2012
Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MHA dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.Invest New Drugs 30(2) 629-38 4/1/2012
Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, Luu T, Somlo G, Goetz M, Swaby R, Shapiro CL, Stearns V, Christos P, Espinoza-Delgado I, Bhalla K, Sparano JAPhase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.Breast Cancer Res Treat 132(3) 1063-72 4/1/2012
Mrózek E, Layman R, Ramaswamy B, Schaaf L, Li X, Ottman S, Shapiro CLPhase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.Clin Breast Cancer 12(2) 151-6 4/1/2012
U S D, Fu CY, Soh KS, Ramaswamy B, Kumar A, Olivo MHighly sensitive SERS detection of cancer proteins in low sample volume using hollow core photonic crystal fiber.Biosens Bioelectron 33(1) 293-8 3/15/2012
Garcia-Villa A, Balasubramanian P, Miller BL, Lustberg MB, Ramaswamy B, Chalmers JJAssessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy.Front Oncol 2 128 1/1/2012
Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C, Jacob ST, Majumder SAnti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal.J Biol Chem 286(49) 42292-302 12/9/2011
Viswanathan S, Ramaswamy BPregnancy-associated breast cancer.Clin Obstet Gynecol 54(4) 546-55 12/1/2011
Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CLPhase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.Clin Breast Cancer 11(4) 221-7 8/1/2011